4-Star Stocks Poised to Pop: PDL BioPharma

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, antibody humanization patent manager PDL BioPharma (Nasdaq: PDLI  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at PDL's business and see what CAPS investors are saying about the stock right now.

PDL facts

Headquarters (founded) Incline Village, Nev. (1986)
Market Cap $886.8 million
Industry Biotechnology
Trailing-12-Month Revenue $362.0 million
Management CEO/Acting CFO John McLaughlin
Chief Accounting Officer Caroline Krumel
Return on Capital (average, past 3 years) 88.2%
Cash/Debt $210.8 million / $410.0 million
Dividend Yield 9.5%
Competitors Amgen
Seattle Genetics

Sources: S&P Capital IQ; Motley Fool CAPS.

On CAPS, 95% of the 901 members who have rated PDL believe the stock will outperform the S&P 500 going forward.

Just last month, All-Star Fool austinhippie highlighted several of PDL's positives:

Looks about worth twice its current market price ... Good Margins ... cash flow is positive and relatively steady although not really growing ... a powerful dividend.

If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its four-star rating, PDL may not be your top choice.

We've found another small-cap play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit From the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1844178, ~/Articles/ArticleHandler.aspx, 10/23/2016 8:40:17 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
PDLI $3.15 Up +0.02 +0.64%
PDL BioPharma CAPS Rating: ***